Clinical Trials Directory

Trials / Terminated

TerminatedNCT00228995

A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia

A Randomized, Double-blind, Placebo-controlled, Study to Assess Changes in Physical Function in Elderly Patients With Idiopathic Anemia of Aging (IAA) Receiving Epoetin Alfa (PROCRIT�)

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
9 (actual)
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · Industry
Sex
All
Age
65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess changes in physical function in elderly patients (\>= 65 years of age) with chronic anemia (Hb \<= 11.0 g/dL) due to anemia of unknown cause and receiving weekly subcutaneous doses of Epoetin alfa (PROCRIT®) versus placebo.

Detailed description

.Some elderly patients have anemia (reduction in hemoglobin level, or low red cell count) without obvious cause. Anemia occurs commonly with aging and is a frequent medical condition in individuals over the age of 65. Physical performance and function is worse in individuals who are anemic. This is a randomized, double-blind, placebo-controlled, multi-center study to assess physical function (to include falls) and fatigue in approximately 80 elderly patients with chronic anemia (anemia present for at least 3 months) and who are receiving weekly Epoetin alfa. The study will also evaluate hemoglobin levels (oxygen carrying protein in red blood cells), safety, fatigue and cognitive function. The study hypothesis is to demonstrate the study drug will be more effective in treatment of chronic anemia than placebo, resulting in the improvement of physical function and subsequent disabilities, with minimal adverse events and the study drug is generally well-tolerated. The patients will receive weekly injections of Epoetin alfa (PROCRIT®) or placebo at a starting dose of 10,000 units administered subcutaneously (under the skin).

Conditions

Interventions

TypeNameDescription
DRUGepoetin alfa

Timeline

Start date
2004-06-01
Completion
2005-09-01
First posted
2005-09-29
Last updated
2011-06-10

Source: ClinicalTrials.gov record NCT00228995. Inclusion in this directory is not an endorsement.